Clinical trial
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung…
NCT00193245 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193245 |
|---|---|
| Title | Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer |
| Official title | A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | AstraZeneca Industry Aventis Pharmaceuticals GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Topotecan, Docetaxel |
| Enrollment | 80 |
| Start date | Nov 1, 2000 |
| Primary completion | Oct 1, 2005 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 28, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: